We are live on ! Find out more

Revolution Medicines

RVMD

Market cap $43.7B

203.77 USD

+0.42

0.21%

At close Updated Sep 11, 4:00 PM EDT

Pre-market

After hours

203.77

0.00

0%

1 day

0.21%

5 days

-2.51%

1 month

-0.87%

3 months

36.55%

6 months

104.61%

Year to date

157.87%

1 year

340.68%

5 years

588.88%

10 years

605.09%

About: Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.

Employees: 883

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 56.5%

Neutral 41.3%

Negative 2.2%

The Motley Fool

Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?

Amgen maintains a massive global footprint and generated over $8.1 billion in free cash flow during its latest fiscal year. Revolution Medicines is a clinical-stage oncology specialist focused on high-stakes breakthrough therapies for RAS-addicted cancers.

Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?

Business Insider

Two scientists made huge bets on 'impossible' cancer treatments. They're finally paying off.

2026 is the year of the cancer breakthrough, with innovations from Revolution Medicines and Moderna. "I'm almost tired of saying paradigm shift, but I haven't figured out a new phrase," one expert said.

Two scientists made huge bets on 'impossible' cancer treatments. They're finally paying off.

Revolution Medicines Got Its Breakthrough—What Moves It Next?

Revolution Medicines NASDAQ: RVMD just landed one of the biggest wins in oncology this year, and the stock barely blinked. On Aug. 26, the FDA approved RASONQUE (daraxonrasib), the first broad RAS-targeted therapy for metastatic pancreatic cancer.

Revolution Medicines Got Its Breakthrough—What Moves It Next?

Zacks Investment Research

Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?

Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock?

Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that The New England Journal of Medicine (NEJM) has published a report describing data from the Phase 1/2 clinical trial evaluating RASONQUE (daraxonrasib), an oral, RAS(ON) multi-selective inhibitor, in patients with previously treated advanced RAS mutant non-small cell lung cancer (NSCLC).

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

Revolution Medicines: Strong Buy RASONQUE FDA Approval And Zoldonrasib PDAC Expansions

Revolution Medicines maintains a strong buy rating following FDA approval of RASONQUE for 2nd-line metastatic PDAC, with significant expansion opportunities ahead. Company's pipeline includes zoldonrasib, targeting G12D-mutant PDAC and NSCLC, with two pivotal phase 3 trials underway in 1st-line settings, leveraging strong prior efficacy data. The company holds $3.9B in cash, supported by recent financings and a $2B Royalty Pharma agreement, providing at least 12 months of operational runway.

Revolution Medicines: Strong Buy RASONQUE FDA Approval And Zoldonrasib PDAC Expansions

Revolution Medicines: RASONQUE's FDA Approval Portends A New Oncology Titan

Revolution Medicines (RVMD) secured rapid FDA approval for RASONQUE, a first-in-class oral RAS(ON) inhibitor targeting metastatic pancreatic cancer. RVMD's multi-selective approach addresses a broad spectrum of RAS mutations, positioning RASONQUE as a potential blockbuster with significant market opportunity. Despite a strong cash position ($3.9B), RVMD will incur substantial losses through 2028, with profitability only projected in 2029 as revenue ramps from global expansion.

Revolution Medicines: RASONQUE's FDA Approval Portends A New Oncology Titan

Revolution Medicines Wins FDA Approval for RASONQUE in Metastatic Pancreatic Cancer

Revolution Medicines NASDAQ: RVMD said the U.S. Food and Drug Administration has approved daraxonrasib under the brand name RASONQUE for certain adults with metastatic pancreatic adenocarcinoma.

Revolution Medicines Wins FDA Approval for RASONQUE in Metastatic Pancreatic Cancer

The Motley Fool

Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales.

It's a cancer medication with immense potential. In clinical testing, the pill was shown to double the survival rate of pancreatic cancer patients.

Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales.

Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent

Revolution Medicines attracted takeover interest but decided to go it alone. This week's FDA approval of its pancreatic cancer pill is the payoff.

Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent

See News Rankings

Price charts implemented using Lightweight Charts™